Monash study unravels another piece of the puzzle in how cancer cells may be targeted by the immune system
Effective immunity hinges on the ability to sense infection and cellular transformation. In humans, there is a specialised molecule on the surface of cells termed MR1. MR1 allows sensing of certain small molecule metabolites derived from cellular and microbial sources; however, the breadth of metabolite sensing is unclear.
Published in PNAS, researchers at the Monash University Biomedicine Discovery Institute (BDI) have identified a form of Vitamin B6 bound to MR1 as a means of engaging tumour-reactive immune cells. The work involved an international collaborative team co-led by researchers from the University of Melbourne.
According to Dr Illing, “Our findings suggest that Vitamin B6 molecules displayed by MR1 represent a means for the immune system to detect altered cellular metabolism/metabolite levels that may distinguish cancer cells,” she said.
“Identification of small molecules/metabolites able to activate immune cells with cancer reactivity is a key step in understanding how small molecule sensing might contribute to anti-cancer immunity.”
Central to this study were the unbiased mass spectrometry analysis of small molecules bound to MR1, the structural resolution of the interactions between MR1 and Vitamin B6, and immunological assays performed by lead authors Dr Mitchell McInerney and Dr Wael Awad at Monash Biomedicine Discovery Institute, and Dr Michael Souter and Mr Yang Kang at the University of Melbourne, Peter Doherty Institute.
While it’s not yet clear if the Vitamin B6 molecule can be utilised in therapeutics, “understanding the breadth of MR1 mediated immunity has the capacity to illuminate routes for therapeutic intervention,” Dr Illing said.
An important aspect of the finding is that MR1 differs very little across individuals – with few known genetic variants in the human population. “Thus, understanding immune activation mediated via MR1 may pave the way for therapeutic interventions with broad utility,” Dr Illing said.
She added that next steps for investigation will confirm whether Vitamin B6 and related molecules are displayed by the MR1 of cancer cells at altered levels to healthy body cells, thus enabling specific cancer targeting, or if other small molecules displayed by MR1 may help differentiate cancerous and healthy cells.
Read the full paper published in PNAS, titled MR1 presents vitamin B6–related compounds for recognition by MR1-reactive T cells
DOI: 10.1073/pnas.2414792121
MEDIA ENQUIRIES
Tania Ewing, Monash University
Media and Communications Contractor
E: taniaewing@taniaewing.com
M: +61 (0) 408 378 422
GENERAL MEDIA ENQUIRIES
For more Monash media stories, visit our news and events site
Monash Media
E: media@monash.edu
T: +61 (0) 3 9903 4840
About the Monash Biomedicine Discovery Institute at Monash University
Committed to making discoveries that will relieve the future burden of disease, Monash Biomedicine Discovery Institute at Monash University brings together more than 120 internationally renowned research teams. Spanning seven discovery programs across Cancer, Cardiovascular Disease, Development and Stem Cells, Infection, Immunity, Metabolism, Diabetes and Obesity, and Neuroscience, Monash BDI is one of the largest biomedical research institutes in Australia. Our researchers are supported by world-class technology and infrastructure, and partner with industry, clinicians and researchers internationally to enhance lives through discovery.